Icatibant Glenmark (Icatibant)

Icatibant works as a competitive antagonist of the bradykinin B2 receptor. By binding to this receptor on vascular endothelial cells, it prevents bradykinin from increasing vascular permeability, thereby limiting edema and the severity of hereditary angioedema attacks.

The prescribed dose of icatibant is determined by the treating physician. In clinical practice, a single 30 mg subcutaneous injection is commonly administered for an acute HAE attack, but exact dosing and repeat administration are individualized.

Safety data for icatibant during pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescriber in consultation with the patient.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

The primary alternative for acute HAE is plasma‑derived or recombinant C1‑esterase inhibitor replacement therapy. Icatibant targets the bradykinin pathway directly, offering a subcutaneous route and rapid onset, whereas C1‑INH products are administered intravenously and replace the deficient protein.

Icatibant prefilled syringes should be stored at 2‑8 °C (refrigerated). Keep them in the original packaging, protect from light, and avoid freezing or shaking the vial. Do not use the product if it has been exposed to temperatures outside this range.

Icatibant is supplied as a 30 mg/0.3 mL prefilled syringe for subcutaneous injection. The injection is typically performed into the abdomen or thigh by a healthcare professional or trained patient, following aseptic technique and the instructions provided by the prescriber.

The most serious risks include severe allergic reactions such as anaphylaxis, marked hypotension, and unexpected angioedema at the injection site. Patients should be observed after administration and instructed to seek immediate medical attention if symptoms of a severe reaction develop.

Icatibant should not be used in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with a history of severe allergic reactions, and it is generally avoided in those receiving other bradykinin B2 antagonists without medical supervision.